Cardiovascular risk and management in chronic kidney disease

Nature Reviews Nephrology

Volumn 5, Issue 5, 2009, Pages 287-296

  Rucker, Diana ^a   Tonelli, Marcello ^b  

^a Div of General Internal Medicine

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CINACALCET; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EZETIMIBE; FIBRIC ACID DERIVATIVE; FOSINOPRIL; GLICLAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; NICOTINIC ACID; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RAMIPRIL; ROSUVASTATIN; SIMVASTATIN; SOTALOL; SPIRONOLACTONE; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; VALSARTAN;

ANEMIA; BLEEDING; BLOOD CLOTTING; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DIALYSIS; DISEASE COURSE; DRUG POTENTIATION; DYSLIPIDEMIA; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INFLAMMATION; KIDNEY TRANSPLANTATION; NONHUMAN; OBESITY; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PHOSPHATE METABOLISM; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SMOKING; CHRONIC KIDNEY FAILURE; RISK FACTOR;

CARDIOVASCULAR DISEASES; HUMANS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 67650376386     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2009.42     Document Type: Review

References (116)

1. weiner, D. E. et al. Chronic kidney disease as a risk factor for cardiovascular disease and all- cause mortality: a pooled analysis of community-based studies. J. Am. Soc. Nephrol. 15, 1307-1315 (2004
2. Sarnak, M. J. et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure research, Clinical Cardiology, and epidemiology and Prevention. Hypertension 42, 1050-1065 (2003
3. Levey A. S. et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann. Intern. Med. 139, 137-147 (2003
4. Gill, J. S. Cardiovascular disease in transplant recipients: current and future treatment strategies. Clin. J. Am. Soc. Nephrol. 3 (Suppl. 2), s29-s37 (2008
5. Shulman, N. B. et al. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 13 (Suppl.), s180-s193 (1989
6. Ezekowitz, J. et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. J. Am. Coll. Cardiol. 44, 1587-1592 (2004
7. Tonelli, M. et al. effect of pravastatin on cardiovascular events in people with chronic kidney disease. Circulation 110, 1557-1563 (2004
8. Collins, R., Armitage, J., Parish, S., Sleigh, P. & Peto, R. MrC/BHF Heart Protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo- controlled trial. Lancet 361, 2005-2016 (2003
9. Garg, A. X., Clark, W. F., Haynes, R. B. & House, A. A. Moderate renal insufficiency and the risk of cardiovascular mortality: results from the NHANes i. Kidney Int. 61, 1486-1494 (2002
10. Menon, V. et al. Cystatin C as a risk factor for outcomes in chronic kidney disease. Ann. Intern. Med. 147, 19-27 (2007
11. Shlipak, M. G. et al. Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease. Ann. Intern. Med. 145, 237-246 (2006
12. Garg, A. X., Kiberd, B. A., Clark, W. F., Haynes, R. B. & Clase, C. M. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANes iii. Kidney Int. 61, 2165-2175 (2002
13. Arnlov, J. et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart study. Circulation 112, 969-975 (2005
14. Foley, R. N., Parfrey, P. S. & sarnak, M. J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 32, s112-s119 (1998
15. Baigent, C., Burbury, K. & wheeler, D. Premature cardiovascular disease in chronic renal failure. Lancet 356, 147-152 (2000
16. Foley, R. N. et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United states Medicare population, 1998 to 1999. J. Am. Soc. Nephrol. 16, 489-495 (2005
17. Foley, R. N., Wang, C. & Collins, A. J. Cardiovascular risk factor profiles and kidney function stage in the Us general population: the NHANes iii study. Mayo Clin. Proc. 80, 1270-1277 (2005
18. Shlipak, M. G. et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 293, 1737-1745 (2005
19. Muntner, P., He, J., Astor, B. C., Folsom, A. R. & Coresh, J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the atherosclerosis risk in communities study. J. Am. Soc. Nephrol. 16, 529-538 (2005
20. Port, F. K. et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am. J. Kidney Dis. 33, 507-517 (1999
21. Foley, r. N. Cardiac disease in chronic uremia: can it explain the reverse epidemiology of hypertension and survival in dialysis patients? Semin. Dial. 17, 275-278 (2004
22. Kasiske, B. L. Hyperlipidemia in patients with chronic renal disease. Am. J. Kidney Dis. 32, s142-s156 (1998
23. Liu, Y. et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 291, 451-459 (2004 (Pubitemid 38129749)
24. Kovesdy, C. P., Astor, B. C., Longenecker, J. C. & Coresh, J. Association of kidney function with serum lipoprotein(a) level: the third National Health and Nutrition examination survey (1991-1994). Am. J. Kidney Dis. 40, 899-908 (2002 (Pubitemid 35265468)
25. Kwan, B. C., Kronenberg, F., Beddhu, S. & Cheung, A. K. Lipoprotein metabolism and lipid management in chronic kidney disease. J. Am. Soc. Nephrol. 18, 1246-1261 (2007
26. Strippoli, G. F. et al. effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 336, 645-651 (2008
27. Shepherd, J. et al. intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets.) study. J. Am. Coll. Cardiol. 51, 1448-1454 (2008
28. Wanner, C. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238-248 (2005 (Pubitemid 41058323)
29. Tonelli, M. et al. effect of pravastatin in people with diabetes and chronic kidney disease. J. Am. Soc. Nephrol. 16, 3748-3754 (2005
30. Williams, M. E., Lacson, E., Jr, Teng, M., Ofsthun, N. & Lazarus, J. M. Hemodialyzed type i and type ii diabetic patients in the Us: characteristics, glycemic control, and survival. Kidney Int. 70, 1503-1509 (2006
31. Kalantar-Zadeh, K. et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care 30, 1049-1055 (2007
32. Feldt-rasmussen, B. is there a need to optimize glycemic control in hemodialyzed diabetic patients? Kidney Int. 70, 1392-1394 (2006
33. Peacock, T. P. et al. Comparison of glycated albumin and hemoglobin A1c levels in diabetic subjects on hemodialysis. Kidney Int. 73, 1062-1068 (2008
34. Combe, C. et al. Kidney Disease Outcomes Quality initiative (K/DOQi) and the Dialysis Outcomes and Practice Patterns study (DOPPs): nutrition guidelines, indicators, and practices. Am. J. Kidney Dis. 44, 39-46 (2004
35. Kalantar-Zadeh, K., Abbott, K. C., Salahudeen, A. K., Kilpatrick, R. D. & Horwich, T. B. survival advantages of obesity in dialysis patients. Am. J. Clin. Nutr. 81, 543-554 (2005
36. Collins, A. J., Ma, J. Z. & Ebben, J. impact of hematocrit on morbidity and mortality. Semin. Nephrol. 20, 345-349 (2000
37. [No authors listed] Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian erythropoietin study Group. BMJ 300, 573-578 (1990).
38. Health and Nutrition examination survey (1991-1994). Am. J. Kidney Dis. 40, 899-908 (2002
39. Kwan, B. C., Kronenberg, F., Beddhu, S. & Cheung, A. K. Lipoprotein metabolism and lipid management in chronic kidney disease. J. Am. Soc. Nephrol. 18, 1246-1261 (2007
40. Strippoli, G. F. et al. effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 336, 645-651 (2008
41. Shepherd, J. et al. intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets.) study. J. Am. Coll. Cardiol. 51, 1448-1454 (2008
42. Wanner, C. et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353, 238-248 (2005 (Pubitemid 41058323)
43. Tonelli, M. et al. effect of pravastatin in people with diabetes and chronic kidney disease. J. Am. Soc. Nephrol. 16, 3748-3754 (2005
44. Williams, M. E., Lacson, E., Jr, Teng, M., Ofsthun, N. & Lazarus, J. M. Hemodialyzed type i and type ii diabetic patients in the Us: characteristics, glycemic control, and survival. Kidney Int. 70, 1503-1509 (2006
45. Kalantar-Zadeh, K. et al. A1C and survival in maintenance hemodialysis patients. Diabetes Care 30, 1049-1055 (2007
46. Feldt-Rasmussen, B. is there a need to optimize glycemic control in hemodialyzed diabetic patients? Kidney Int. 70, 1392-1394 (2006
47. Peacock, T. P. et al. Comparison of glycated albumin and hemoglobin A1c levels in diabetic subjects on hemodialysis. Kidney Int. 73, 1062-1068 (2008
48. Combe, C. et al. Kidney Disease Outcomes Quality initiative (K/DOQi) and the Dialysis Outcomes and Practice Patterns study (DOPPs): nutrition guidelines, indicators, and practices. Am. J. Kidney Dis. 44, 39-46 (2004
49. Kalantar-Zadeh, K., Abbott, K. C., salahudeen, A. K., Kilpatrick, R. D. & Horwich, T. B. survival advantages of obesity in dialysis patients. Am. J. Clin. Nutr. 81, 543-554 (2005
50. Collins, A. J., Ma, J. Z. & ebben, J. impact of hematocrit on morbidity and mortality. Semin. Nephrol. 20, 345-349 (2000
51. [No authors listed] Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian erythropoietin study Group. BMJ 300, 573-578 (1990
52. Besarab, A. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 339, 584-590 (1998
53. Singh, A. K. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355, 2085-2098 (2006
54. Rossert, J. et al. effect of early correction of anemia on the progression of CKD. Am. J. Kidney Dis. 47, 738-750 (2006
55. Drueke, T. B. et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 355, 2071-2084 (2006
56. Pfeffer, M. A. Critical missing data on erythropoiesis-stimulating agents in CKD: first beat placebo. Am. J. Kidney Dis. 51, 366-369 (2008
57. Block, G. A., Hulbert-Shearon, T. E., Levin, N. W. & Port, F. K. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. 31, 607-617 (1998
58. London, G. M. et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol. Dial. Transplant. 18, 1731-1740 (2003
59. Goodman, w. G. et al. vascular calcification in chronic kidney disease. Am. J. Kidney Dis. 43, 572-579 (2004
60. Kestenbaum, B. et al. serum phosphate levels and mortality risk among people with chronic kidney disease. J. Am. Soc. Nephrol. 16, 520-528 (2005
61. Kramer, H., Toto, R., Peshock, R., Cooper, R. & victor, R. Association between chronic kidney disease and coronary artery calcification: the Dallas Heart study. J. Am. Soc. Nephrol. 16, 507-513 (2005 (Pubitemid 41725148)
62. Block, G. A., raggi, P., Bellasi, A., Kooienga, L. & Spiegel, D. M. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 71, 438-441 (2007
63. Suki, W. N. et al. effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int. 72, 1130-1137 (2007
64. London, G. M., Marchais, S. J., Guerin, A. P. & Metivier, F. Arteriosclerosis, vascular calcifications and cardiovascular disease in uremia. Curr. Opin. Nephrol. Hypertens. 14, 525-531 (2005
65. Tonelli, M., Sacks, F., Pfeffer, M., Gao, Z. & Curhan, G. relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112, 2627-2633 (2005
66. Thadhani, R. Targeted ablation of the vitamin D 1á-hydroxylase gene: getting to the heart of the matter. Kidney Int. 74, 141-143 (2008
67. Harnett, J. D., Kent, G. M., Barre, P. E., Taylor, R. & Parfrey, P. S. risk factors for the development of left ventricular hypertrophy in a prospectively followed cohort of dialysis patients. J. Am. Soc. Nephrol. 4, 1486-1490 (1994
68. Zoccali, C. et al. Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression. Kidney Int. 65, 1492-1498 (2004 (Pubitemid 38406992)
69. Stack, A. G. & Saran,R . Clinical correlates and mortality impact of left ventricular hypertrophy among new esrD patients in the United states. Am. J. Kidney Dis. 40, 1202-1210 (2002
70. Culleton, B. F. et al. effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 298, 1291-1299 (2007
71. Deckert, T. et al. Microalbuminuria. implications for micro- and macrovascular disease. Diabetes Care 15, 1181-1191 (1992
72. Anavekar, N. S. & Pfeffer, M. A. Cardiovascular risk in chronic kidney disease. Kidney Int. (Suppl.) s11-s15 (2004
73. De Zeeuw, D. et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from reNAAL. Kidney Int. 65, 2309-2320 (2004 (Pubitemid 38670018)
74. Stenvinkel, P. & Alvestrand, A. inflammation in end-stage renal disease: sources, consequences, and therapy. Semin. Dial. 15, 329-337 (2002
75. Pecoits-Filho, R., Barany, P., Lindholm, B., Heimburger, O. & stenvinkel, P. interleukin-6 is an independent predictor of mortality in patients starting dialysis treatment. Nephrol. Dial. Transplant. 17, 1684-1688 (2002
76. Shlipak, M. G. et al. elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation 107, 87-92 (2003
77. Knoll, G. A. et al. Thrombophilia and the risk for hemodialysis vascular access thrombosis. J. Am. Soc. Nephrol. 16, 1108-1114 (2005
78. Vaziri, N. D., Gonzales, E. C., Wang, J. & Said, S. Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: effect of hemodialysis. Am. J. Kidney Dis. 23, 828-835 (1994
79. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324, 71-86 (2002
80. Lucius, R., Gallinat, S., Busche, S., rosenstiel, P. & Unger, T. Beyond blood pressure: new roles for angiotensin ii. Cell. Mol. Life Sci. 56, 1008-1019 (1999
81. Mann, J. F., Gerstein, H. C., Pogue, J., Bosch, J. & Yusuf, S. renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPe randomized trial. Ann. Intern. Med. 134, 629-636 (2001
82. Balamuthusamy, S. et al. renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis. Am. Heart J. 155, 791-805 (2008
83. Zannad, F. et al. Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int. 70, 1318-1324 (2006
84. Yusuf, S. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358, 1547-1559 (2008
85. Mann, J. F. et al. renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTArGeT study): a multicentre, randomised, double-blind, controlled trial. Lancet 372, 547-553 (2008
86. Vaziri, N. D. effect of chronic renal failure on nitric oxide metabolism. Am. J. Kidney Dis. 38, s74-s79 (2001
87. Himmelfarb, J. relevance of oxidative pathways in the pathophysiology of chronic kidney disease. Cardiol. Clin. 23, 319-330 (2005
88. Tepel, M., Van der Giet, M., statz, M., Jankowski, J. & Zidek, w. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 107, 992-995 (2003
89. Boaz, M. et al. secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (sPACe): randomised placebo-controlled trial. Lancet 356, 1213-1218 (2000
90. Robinson, K., Mayer, e. & Jacobsen, D. w. Homocysteine and coronary artery disease. Cleve. Clin. J. Med. 61, 438-450 (1994
91. Menon, V. et al. relationship between homocysteine and mortality in chronic kidney disease. Circulation 113, 1572-1577 (2006 (Pubitemid 43739416)
92. Bostom, A. G. et al. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int. 49, 147-152 (1996
93. Jamison, R. L. et al. effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 298, 1163-1170 (2007
94. Bailie, G. R. et al. Patterns of medication use in the rri-CKD study: focus on medications with cardiovascular effects. Nephrol. Dial. Transplant. 20, 1110-1115 (2005
95. Lahoz, C. et al. Achievement of therapeutic goals and utilization of evidence-based cardiovascular therapies in coronary heart disease patients with chronic kidney disease. Am. J. Cardiol. 101, 1098-1102 (2008
96. Parikh, N. I. et al. Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control. Arch. Intern. Med. 166, 1884-1891 (2006
97. Mc Cullough, P. A. et al. Benefits of aspirin and â-blockade after myocardial infarction in patients with chronic kidney disease. Am. Heart J. 144, 226-232 (2002
98. Berger, A. K., Duval, S. & Krumholz, H. M. Aspirin, â-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J. Am. Coll. Cardiol. 42, 201-208 (2003
99. Charytan, D. et al. The use of invasive cardiac procedures after acute myocardial infarction in long-term dialysis patients. Am. Heart J. 152, 558-564 (2006
100. Freeman, R. V. et al. influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein iib/iiia inhibitors. J. Am. Coll. Cardiol 41, 718-724 (2003
101. Januzzi, J. L., Jr, snapinn, S. M., DiBattiste, P. M., Jang, I. K. & Theroux, P. Benefits and safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: results from the Platelet receptor inhibition in ischemic syndrome Management in Patients Limited by Unstable signs and symptoms (PrisM-PLUs) trial. Circulation 105, 2361-2366 (2002
102. Best, P. J. et al. The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the reduction of events During Observation (CreDO) trial. Am. Heart J. 155, 687-693 (2008
103. Best, P. J. et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J. Am. Coll. Cardiol. 39, 1113-1119 (2002
104. Stigant, C., izadnegahdar, M., Levin, A., Buller, C. E. & Humphries, K. H. Outcomes after percutaneous coronary interventions in patients with CKD: improved outcome in the stenting era. Am. J. Kidney Dis. 45, 1002-1009 (2005
105. Attallah, N., Yassine, L., Fisher, K. & Yee, J. risk of bleeding and restenosis among chronic kidney disease patients undergoing percutaneous coronary intervention. Clin. Nephrol. 64, 412-418 (2005
106. Lemos, P. A. et al. impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents. Am. J. Cardiol. 95, 167-172 (2005
107. Liu, J. Y. et al. risks of morbidity and mortality in dialysis patients undergoing coronary artery bypass surgery. Northern New england Cardiovascular Disease study Group. Circulation 102, 2973-2977 (2000
108. IX, J. H. et al. Association of chronic kidney disease with clinical outcomes after coronary revascularization: the Arterial revascularization Therapies study (ArTs). Am. Heart J. 149, 512-519 (2005
109. Gaede, P. et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N. Engl. J. Med. 348, 383-393 (2003 (Pubitemid 36159355)
110. KDOQi. KDOQi Clinical Practice Guidelines and Clinical Practice recommendations for Diabetes and Chronic Kidney Disease. Am. J. Kidney Dis. 49, s12-s154 (2007
111. K/DOQi workgroup. K/DOQi clinical practice guidelines for cardiovascular disease in dialysis patients. Am. J. Kidney Dis. 45, s1-s153 (2005
112. Levin, A. et al. Guidelines for the management of chronic kidney disease. CMAJ 179, 1154-1162 (2008
113. Charytan, D. & Kuntz, R. E. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int. 70, 2021-2030 (2006
114. Brenner, B. M. et al. effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 345, 861-869 (2001
115. Lewis, e. J. et al. renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851-860 (2001
116. Breslow, L. H. The Best Pharmaceuticals for Children Act of 2002: the rise of the voluntary incentive structure and congressional refusal to require pediatric testing. Harvard J. Legis. 40, 133-193 (2003